Eterna Therapeutics earnings were -$46.1M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ERNA earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$8.2M, up 42.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ERNA reported annual earnings of -$44.6M, with 105.5% growth.
Eterna Therapeutics Earnings Reports & History FAQ
What were Eterna Therapeutics's earnings last quarter?
On ERNA's earnings call on Invalid Date, Eterna Therapeutics (NASDAQ: ERNA) reported Q1 2025 earnings per share (EPS) of -$0.15, up 87.8% year over year. Total ERNA earnings for the quarter were -$8.20 million. In the same quarter last year, Eterna Therapeutics's earnings per share (EPS) was -$1.23.
Is Eterna Therapeutics profitable or losing money?
As of the last Eterna Therapeutics earnings report, Eterna Therapeutics is currently losing money. Eterna Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$46.09 million, a 101.29% increase year over year.
What was ERNA's earnings growth in the past year?
As of Eterna Therapeutics's earnings date in Invalid Date, Eterna Therapeutics's earnings has grown year over year. ERNA earnings in the past year totalled -$46.11 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.